Wealth Enhancement Advisory Services LLC Acquires 66,789 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Wealth Enhancement Advisory Services LLC raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 244.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 94,100 shares of the company's stock after buying an additional 66,789 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.11% of CRISPR Therapeutics worth $3,202,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in CRISPR Therapeutics by 39.1% in the first quarter. SG Americas Securities LLC now owns 29,341 shares of the company's stock valued at $998,000 after buying an additional 8,240 shares during the period. Avanza Fonder AB acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $866,000. Farther Finance Advisors LLC lifted its stake in CRISPR Therapeutics by 46.7% in the first quarter. Farther Finance Advisors LLC now owns 5,626 shares of the company's stock valued at $186,000 after buying an additional 1,792 shares during the period. NBC Securities Inc. lifted its stake in CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after buying an additional 1,563 shares during the period. Finally, Green Alpha Advisors LLC lifted its stake in CRISPR Therapeutics by 132.9% in the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock valued at $1,952,000 after buying an additional 32,732 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRSP has been the topic of several recent analyst reports. Chardan Capital reissued a "buy" rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Thursday. The Goldman Sachs Group dropped their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Barclays lowered their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research report on Thursday. Finally, Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Trading Up 1.7%

CRISPR Therapeutics stock traded up $0.79 during trading on Friday, hitting $47.49. 15,070,469 shares of the company were exchanged, compared to its average volume of 1,857,545. The business's 50 day moving average is $39.48 and its 200 day moving average is $40.50. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $63.68. The company has a market capitalization of $4.10 billion, a P/E ratio of -10.51 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the prior year, the company posted ($1.43) EPS. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. Equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider now owns 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.30% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.